Cancer has become a huge public health issue all around the world. The focus of research
is on innovative cancer therapy techniques that include the disease's unique targets. Among …

EGFR‐positive non‐small‐cell lung cancer (NSCLC) due to primary mutation (EGFR DEL19
& L858R) has been recognized as a crucial mediator of tumor progression. This led to the …

Background The occurrence and development of cancer could be promoted by abnormally
competing endogenous RNAs (ceRNA) network. This article aims to determine the …

Lung cancer is the prime cause of cancer-related deaths globally, with a contribution of 85%
from non-small cell lung cancer. Before a few decades back, conventional chemotherapy …

The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is continuously
producing new variants, necessitating effective therapeutics. Patients are not only …

Background: The development of various targeted therapies against Epidermal Growth
Factor Receptor (EGFR) has been a major step in therapeutic advancements in lung cancer …

Cancer is a complicated, multifaceted disease that can impact any organ in the body.
Various chemotherapeutic agents have a low selectivity and are very toxic when used alone …

Objectives The irreversible epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR TKIs) afatinib and dacomitinib are approved for first-line treatment of EGFR mutation …

Introduction Although tyrosine kinase inhibitors (TKIs) have improved the efficacy of
treatment for non-small cell lung cancer (NSCLC), the accessibility of TKIs is limited due to …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib,
erlotinib, and afatinib, are widely used in clinical practice and remarkably effective in …